According to GuruFocus Insider Data, the largest insider sells during the past week were: Keryx Biopharmaceuticals Inc., Oracle Corporation, Qualcomm Inc. and Gilead Sciences Inc.
The overall trend of insiders is illustrated in the chart below:
Keryx Biopharmaceuticals Inc. (NASDAQ:KERX): CFO James F. Oliviero III Sold 292,483 Shares
CFO James F Oliviero III sold 292,483 shares of KERX stock on 03/21/2014 at the average price of $15.14. James F. Oliviero III owns at least 304,417 shares after this. The price of the stock has decreased by 1.98% since.
- Warning! GuruFocus has detected 3 Warning Signs with KERX. Click here to check it out.
- KERX 15-Year Financial Data
- The intrinsic value of KERX
- Peter Lynch Chart of KERX
Keryx Biopharmaceuticals Inc is a Delaware corporation incorporated in Delaware in October 1998. Keryx Biopharmaceuticals Inc. has a market cap of $1.35 billion; its shares were traded at around $14.84.
In its fourth quarter ended Dec. 31, 2013, Keryx Biopharmaceuticals Inc. reported net loss of $17.7 million, or $0.21 per share, compared to a net loss of $6.6 million a year ago.
Oracle Corporation (NYSE:ORCL): Chairman of the Board Jeffrey Henley Sold 750,000 Shares
Chairman of the Board Jeffrey Henley sold 750,000 shares of ORCL stock on 03/21/2014 at the average price of $38.26. Jeffrey Henley owns at least 1,934,516 shares after this. The price of the stock has decreased by 1.99% since.
Oracle Corporation was incorporated in 2005 as a Delaware corporation and is the successor to operations originally begun in June 1977. Oracle Corporation has a market cap of $167.21 billion; its shares were traded at around $37.50 with a P/E ratio of 15.70 and P/S ratio of 4.61. The dividend yield of Oracle Corporation stocks is 0.96%. Oracle Corporation had an annual average earnings growth of 19.40% over the past 10 years. GuruFocus rated Oracle Corporation the business predictability rank of 4.5-star.
Oracle Corporation recently announced fiscal third quarter 2014 total revenues up 4% to $9.3 billion and GAAP operating income up 7% to $3.6 billion. GAAP net income was $3.1 billion.
Qualcomm Inc. (NASDAQ:QCOM): Executive Chairman Paul E. Jacobs Sold 210,000 Shares
Executive Chairman of Qualcomm Inc. (NASDAQ:QCOM) Paul E. Jacobs sold 210,000 shares during the past week at an average price of $78.19.
Qualcomm Inc. (Qualcomm) in the state of Delaware, develops designs, manufactures and markets digital wireless telecommunications products and services. Qualcomm Inc. has a market cap of $132.23 billion; its shares were traded at around $78.19 with a P/E ratio of 20.0 and P/S ratio of 5.36. The dividend yield of Qualcomm Inc. stocks is 1.79%. Qualcomm Inc. had an annual average earnings growth of 14.00% over the past 10 years. GuruFocus rated Qualcomm Inc. the business predictability rank of 5-star.
CEO Steven M. Mollenkopf sold 23,125 shares of QCOM stock on 03/11/2014 at the average price of $77.1.
Gilead Sciences Inc. (NASDAQ:GILD): EVP, R&D and CSO Norbert W. Bischofberger Sold 90,000 Shares
EVP, R&D and CSO Norbert W. Bischofberger sold 90,000 shares of GILD stock on 03/14/2014 at the average price of $75.89. Norbert W. Bischofberger owns at least 119,302 shares after this. The price of the stock has decreased by 5.03% since.
Gilead Sciences Inc. was incorporated in Delaware on June 22, 1987. Gilead Sciences Inc. has a market cap of $110.86 billion; its shares were traded at around $72.07 with a P/E ratio of 39.50 and P/S ratio of 10.90. Gilead Sciences Inc. had an annual average earnings growth of 8.20% over the past five years.
In its fourth quarter of 2014, Gilead Sciences Inc. generated product sales of $3.04 billion – representing a 21% increase over the prior year quarter. Net income from the fourth quarter was $791.4 million ($0.47 per diluted share), compared to $762.5 million a year ago.
For the complete list of stocks that bought and sold by their company executives, go to: Insider Buys.